Detection of metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic castration-resistant prostate cancer (CRPC)
| Autor: | F. E. Nathan, C. S. Higano, Evan Y. Yu |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Zibotentan business.industry Definitive Therapy Disease Castration resistant urologic and male genital diseases medicine.disease Placebo Androgen deprivation therapy Prostate cancer chemistry.chemical_compound chemistry Internal medicine medicine In patient business |
| Zdroj: | Journal of Clinical Oncology. 29:4655-4655 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 4655 Background: Many patients with biochemical relapse after definitive therapy for prostate cancer receive androgen deprivation therapy. PSA levels eventually will rise despite castrate levels of... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|